Wnt pathway antagonists, SFRP1, SFRP2, SOX17, and PPP2R2B, are methylated in gliomas and SFRP1 methylation predicts shorter survival

• Autorzy: Majchrzak-Celinska A. , Slocinska M. , Barciszewska A.-M. , Nowak S. , Baer-Dubowska W.
• Języki publikacji: EN

Abstrakty

EN

• Wydawca: -
• Czasopismo: Journal of Applied Genetics
• Rocznik: 2016
• Tom: 57
• Numer: 2
• Opis fizyczny: p.189-197,fig.,ref.

Twórcy

autor

Majchrzak-Celinska A.

• Department of Pharmaceutical Biochemistry, Poznan University of Medical Sciences, Poznan, Poland

autor

Slocinska M.

• Department of Pharmaceutical Biochemistry, Poznan University of Medical Sciences, Poznan, Poland

autor

Barciszewska A.-M.

• Department and Clinic of Neurosurgery and Neurotraumatology, Poznan University of Medical Sciences, Poznan, Poland

autor

Nowak S.

• Department and Clinic of Neurosurgery and Neurotraumatology, Poznan University of Medical Sciences, Poznan, Poland

autor

Baer-Dubowska W.

• Department of Pharmaceutical Biochemistry, Poznan University of Medical Sciences, Poznan, Poland

Identyfikatory

DOI

10.1007/s13353-015-0312-7